Table 2.
Selected clinical trials including children with T-ALL.
| Target | Molecule | Patients | ClinicalTrials.gov Identifier/References |
|---|---|---|---|
| CDK4/6 | palbociclib+chemotherapy | Up to 21 years old with R/R ALL | NCT03515200 [22] |
| palbociclib+sorafenib, decitabine, dexamethasone | 15 years old and older with R/R leukemia | NCT03132454 [22] | |
| palbociclib+chemotherapy | 12 months to 31 years old with R/R ALL or LL | NCT03792256 | |
| ribociclib+everolimus, dexamethasone | 1 to 30 years old with R/R ALL | NCT03740334 | |
| PI3K/Akt/mTOR | everolimus+HyperCVAD chemotherapy | 10 years old and older with R/R ALL | NCT00968253 [47] |
| everolimus+prednisone, vincristine, PEG-asparaginase, doxorubicin | 18 months to 21 years old with R/R ALL | NCT01523977 [48] | |
| BCL-2 | venetoclax+chemotherapy | Up to 25 years old with R/R ALL | NCT03236857 |
| venetoclax+navitoclax. chemotherapy | 4 years old and older with R/R ALL or LL | NCT03181126 | |
| CD5 | CAR T cells targeting CD5 | Up to 75 years old with T-cell malignancies | NCT03081910 |
| CD38 | daratumumab+chemotherapy | 1 to 30 years old with | NCT03384654 |